Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer

Lenvatinib is approved for the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day, but its high toxicity often necessitates dose reductions and interruptions. To clarify the efficacy and safety of the reduced dose-initiation of lenv...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yomi Nakashima, Ichiro Horie, Haruka Arimori, Mayu Ueda, Shinpei Nishikido, Yuta Nakamura, Keita Nakaji, Tetsuro Niri, Ayaka Sako, Ai Haraguchi, Toshiyuki Ikeoka, Satoru Akazawa, Akie Moriuchi, Misa Imaizumi, Toshiro Usa, Atsushi Kawakami
Format:	Artigo
Jezik:	Inglês
Izdano:	The Japan Endocrine Society 2025-12-01
Serija:	Endocrine Journal
Teme:	lenvatinib tyrosine kinase inhibitor radioiodine thyroid cancer
Online pristup:	https://www.jstage.jst.go.jp/article/endocrj/72/12/72_EJ25-0251/_html/-char/en
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!